Medtronic Ordered to Pay $88 Million in First Federal Hernia Mesh Trial

A federal jury in Boston ordered Medtronic (NYSE: MDT) to pay $88 million in damages to a plaintiff and his wife in the first of thousands of lawsuits over hernia-repair mesh implants made by its Covidien subsidiary. The verdict marks a significant development in the widespread litigation concerning the medical devices.

The Jury's Findings

The jury concluded on Tuesday that Covidien failed to provide adequate warnings about the potential risks associated with its hernia mesh product. The case was brought by Larry Patterson, an Alabama man who received the implant in 2017 and later required major reconstructive surgery after the device failed, according to his complaint.

While the award is substantial, the jury did not find that Covidien committed fraud and declined to award punitive damages. The verdict was confirmed in statements from both Medtronic and the plaintiff's legal counsel.

Company Response and Next Steps

Ad

Medtronic has announced its intention to challenge the outcome. In a statement, the company said it plans to contest the verdict through post-trial motions and, if necessary, an appeal. Medtronic defended its products, stating they have been "used safely and effectively in millions of patients" for over two decades and that hernia mesh is the standard of care for most hernia repairs.

Broader Implications

This three-week trial was the first to reach a verdict out of thousands of similar cases consolidated in federal court against the company. Such initial trials, often called bellwether cases, are closely watched as their outcomes can influence legal strategies and settlement negotiations for the remaining lawsuits.

According to the plaintiff's attorney, Timothy O’Brien, the $88 million award is the largest verdict to date among more than a dozen trials involving hernia and transvaginal mesh products that have been litigated. This result could set a high benchmark for future claims against the company.